MGNX (MacroGenics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MGNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | Sell | — | — |
| 2026-08-18 | Ezio Bonvini | Sr VP, Research & CSO | M | — | — |
| 2026-05-20 | Margaret Liu | Director | M | — | — |
| 2026-05-20 | Scott Thomas Jackson | Director | M | — | — |
| 2026-05-20 | JAY PHILIP SIEGEL | Director | M | — | — |
| 2026-05-20 | Federica F. O'Brien | Director | M | — | — |
| 2026-05-20 | Karen Jean Ferrante | Director | M | — | — |
| 2026-05-20 | Scott Koenig | Director | A | — | — |
| 2026-05-20 | WILLIAM K HEIDEN | Director | M | — | — |
| 2026-05-20 | Meenu Chhabra | Director | M | — | — |
| 2026-05-20 | EDWARD HURWITZ | Director | M | — | — |
| 2026-05-20 | DAVID C STUMP | Director | M | — | — |
| 2026-02-17 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | — | — |
| 2026-02-17 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | MIXED | — | — |
| 2026-02-17 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | — | — |
| 2026-02-17 | Scott Koenig | Director | M | — | — |
| 2026-02-17 | James Karrels | SVP and CFO | MIXED | — | — |
| 2026-02-17 | Eric Blasius Risser | President and CEO | MIXED | — | — |
| 2026-02-17 | Ezio Bonvini | Sr VP, Research & CSO | MIXED | — | — |
| 2026-02-10 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | — | — |
| 2026-02-10 | Scott Koenig | Director | M | — | — |
| 2026-02-10 | Eric Blasius Risser | President and CEO | MIXED | — | — |
| 2026-02-10 | James Karrels | SVP and CFO | MIXED | — | — |
| 2026-02-10 | Jeffrey Stuart Peters | Senior VP, GC, and Secretary | MIXED | — | — |
| 2026-02-10 | Ezio Bonvini | Sr VP, Research & CSO | MIXED | — | — |
| 2026-02-10 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | — | — |
| 2025-12-10 | Beth Ann Smith | VP, Controller & Treasurer | A | — | — |
| 2025-08-21 | WILLIAM K HEIDEN | Director | Buy | — | — |
| 2025-08-19 | Thomas Spitznagel | Sr VP, Technical Ops | A | — | — |
| 2025-08-19 | Jeffrey Stuart Peters | Senior VP and General Counsel | A | — | — |
| 2025-08-15 | Eric Blasius Risser | President and CEO | A | — | — |
| 2025-08-15 | Scott Koenig | Director | M | — | — |
| 2025-05-22 | Margaret Liu | Director | M | — | — |
| 2025-05-22 | Meenu Chhabra | Director | M | — | — |
| 2025-05-22 | Scott Thomas Jackson | Director | M | — | — |
| 2025-05-22 | Federica F. O'Brien | Director | M | — | — |
| 2025-05-22 | WILLIAM K HEIDEN | Director | M | — | — |
| 2025-05-22 | JAY PHILIP SIEGEL | Director | M | — | — |
| 2025-05-22 | DAVID C STUMP | Director | M | — | — |
| 2025-05-22 | Karen Jean Ferrante | Director | M | — | — |
| 2025-05-22 | EDWARD HURWITZ | Director | M | — | — |
| 2025-02-19 | James Karrels | SVP, CFO and Secretary | MIXED | — | — |
| 2025-02-19 | Ezio Bonvini | Sr VP, Research & CSO | M | — | — |
| 2025-02-19 | Stephen L. Eck | Chief Medical Officer | MIXED | — | — |
| 2025-02-19 | Eric Blasius Risser | Chief Operating Officer | MIXED | — | — |
| 2025-02-19 | Scott Koenig | President and CEO | M | — | — |
| 2025-02-19 | Beth Ann Smith | VP, Controller & Treasurer | MIXED | — | — |
| 2025-02-19 | Jeffrey Stuart Peters | Senior VP and General Counsel | MIXED | — | — |
| 2025-02-19 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | — | — |
| 2025-02-11 | Thomas Spitznagel | Sr VP, Technical Ops | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,929,963 | — |
| — | 10%+ Owner | 9,079,963 | — |
| — | — | 2,208,762 | — |
| — | 10%+ Owner | 2,013,509 | — |
| — | Director | 1,752,820 | — |
| — | Director | 1,708,716 | — |
| — | Director | 1,301,734 | — |
| — | President and CEO | 1,294,720 | — |
| — | 10%+ Owner | 962,819 | — |
| — | SVP and CFO | 306,368 | — |
| — | Sr VP, Research & CSO | 185,799 | — |
| — | Director | 114,750 | — |
| — | President and CEO | 83,602 | — |
| — | Director | 59,435 | — |
| — | SVP, Product Dev. & Regulatory | 49,863 | — |
| — | Sr VP, Technical Ops | 38,543 | — |
| — | Chief Medical Officer | 29,377 | — |
| — | Sr VP, Clinical Dev. & CMO | 18,930 | — |
| — | SVP & General Counsel | 16,986 | — |
| — | Director | 14,750 | — |
| — | Director | 14,750 | — |
| — | Director | 14,750 | — |
| — | Director | 14,750 | — |
| — | Director | 14,750 | — |
| — | Director | 14,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MGNX quote page; the site-wide leaderboard is on the insider transactions hub.